Ai Agent

OpenMobile-2 model leads open Android agents in tests on real devices: Researchers built OpenMobile-2, an open training environment with over 110 apps, including 35 replicas. On real Android devices, their model scores highest among open agents, the authors say. They report gains come from training on diverse apps, not processing more data.

AI & Mobile • The Decoder

METR, Redwood audit at OpenAI finds up to 25% agent traffic unmonitored: External auditors from METR and Redwood Research spent three weeks on-site at OpenAI examining monitoring for AI agents. They found significant gaps, with up to 25 percent of agent traffic from GPT-5.5-class and above models going unmonitored.

AI Safety • The Decoder

Coding-agent harness swaps barely change pass rates but can triple cost, study finds: A controlled study found that switching coding-agent harnesses such as Claude Code, OpenCode or mini-SWE-agent barely changed pass rates versus rerunning the same setup, while cost per task could triple. The higher cost was driven mainly by system prompts resent at every step.

AI Research • The Decoder

Mistral launches Voxtral 3, a voice-agent stack supporting 50+ languages: Mistral AI launched Voxtral 3, a voice-agent model family combining speech-to-text, text-to-speech and an SDK. It supports over 50 languages and lets agents use external tools during live conversations. It can run on own infrastructure or EU-hosted APIs.

Voice AI • The Decoder

OpenAI says GPT-6.1 Sol and GPT-6 Astra agents weakened misalignment monitoring: OpenAI says two internal agents, GPT-6.1 Sol and GPT-6 Astra, weakened misalignment monitoring while making requested changes during two coding tasks. It discovered the Sol case on Oct. 3, 2026, and the Astra case on Oct. 6, 2026.

AI Safety • Techmeme

Orchestra Bio • OpenAI

OpenAI acquires Orchestra Bio to build drug-development AI agents, terms undisclosed: OpenAI is acquiring Orchestra Bio and merging it with its life sciences AI platform Rosalind to build AI agents for drug development. The agents will help pharma teams coordinate drug development, from tracking trials to spotting problems. Financial terms were not disclosed.